Company profile: Nouscom
1.1 - Company Overview
Company description
- Provider of an immunotherapy platform for cancer, creating modified viral vector vaccines with engineered vectors optimized to express long strings of tumor neoantigens; products: NOUS-209 (off-the-shelf for mismatch repair deficiency and microsatellite instability), NOUS-PEV (personalized vaccine encoding up to 60 neoantigens via VENUS), NOUS-THV-001 (oncolytic Herpes Virus expressing immunomodulatory molecules).
Products and services
- NOUS-PEV: A personalized vaccine tailored to individual tumor mutanomes, encoding up to 60 neoantigens selected using the VENUS algorithm to provoke patient-specific anti-tumor immune activation
- NOUS-209: An off-the-shelf cancer immunotherapy targeting mismatch repair–deficient, microsatellite‑instable tumors by encoding 209 unique frame shift peptide cancer neoantigens for selective tumor cell killing
- NOUS-THV-001: An oncolytic Herpes Virus engineered to selectively infect and kill cancer cells while expressing immunomodulatory molecules that elevate anti-tumor immune responses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nouscom
Selexys Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexys Pharmaceuticals company profile →
Nascent Biotech
HQ: United States
Website
- Description: Provider of therapeutic antibodies and platform technologies. Pritumumab is a natural human IgG antibody targeting ecto-domain vimentin on adenocarcinomas, including brain cancers and melanoma; MultiPharm is a multi-agent (antibodies and/or cytokines) platform for potential treatment of cancer, diabetes, autoimmunity, and transplantation; and CLNH5 is a patented technology with four patents awarded by the United States Patent Office.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nascent Biotech company profile →
ADC Therapeutics
HQ: Switzerland
Website
- Description: Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Therapeutics company profile →
Oncolytics Biotech
HQ: Canada
Website
- Description: Provider of oncolytic virus therapeutics for a broad range of cancers, developing Pelareorep, a nonpathogenic oncolytic virus that selectively replicates in cancer cells to generate immune responses, enhance oncology treatments, and extend patient survival.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncolytics Biotech company profile →
Syntimmune
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology drug candidates for a wide range of autoimmune diseases, advancing differentiated therapies based on expertise in neonatal Fc receptor (FcRn) biology and its role in the pathogenesis of IgG-mediated conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syntimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nouscom
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nouscom
2.2 - Growth funds investing in similar companies to Nouscom
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nouscom
4.2 - Public trading comparable groups for Nouscom
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →